⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 1996Melanoma Research

The case for therapeutic vaccines

Angus Dalgleish

View at Publisher

Ask AI

Bookmark

Share

Abstract

Division of Oncology, Department of Cellular and Molecular Sciences, St George's Hospital Medical School, Jenner Wing, Cranmer Terrace, London SW17 ORE, UK. Fax: (+44) 181 725 2992

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Angus Dalgleish (1996) studied this question.

synapsesocial.com/papers/6a10df1a8102eb4b66ee9581 https://doi.org/10.1097/00008390-199602000-00002

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Single-Stage excision and sentinel lymph node biopsy in selected patients with cutaneous melanoma: a monocentric retrospective cohort studyMelanoma Research · Fri,
2Prognostic value of circulating tumor cells in stage III and IV melanoma: a systematic review and meta-analysisMelanoma Research · Fri,
3Comprehensive analysis and external validation of a glycolysis-related gene signature as a prognostic index for skin cutaneous melanomaMelanoma Research · Mon,
4Comprehensive role of fluorine-18-labeled fluorodeoxyglucose PET/computed tomography across the disease course of primary malignant melanoma of the esophagusMelanoma Research · Fri,
5Dissociation between systemic inflammatory markers and the tumor microenvironment in predicting sentinel lymph node metastasis in cutaneous melanomaMelanoma Research · Tue,

More from Melanoma Research

Association between perioperative antidepressant use and postoperative outcomes after cutaneous melanoma resectionMon,
Transcriptomic immune subtyping and connectivity mapping nominate DNA methyltransferase inhibitors for immunedepleted melanomaWed,
DPM2 promotes melanoma progression and serves as a prognostic factorThu,
Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literatureMon,
Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institutionSat,